BioSpace News Archive

Policy

Health Canada Approves ERLEADA™ (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer

ERLEADA™ decreased the risk of metastasis or death in patients by 70 per cent and improved median metastasis-free survival by more than two years

July 4, 2018
·
5 min read
Drug Development

Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine

In Patients with Hereditary ATTR Amyloidosis, Patisiran Treatment Improved Polyneuropathy and Quality of Life Relative to Placebo

July 4, 2018
·
12 min read
Ipsen announces new clinical data to be presented at ISPRM 2018 demonstrating commitment to neurotoxin research

Ipsen announced that its neurotoxin portfolio will be the subject of 13 abstracts at the 12th International Society of Physical and Rehabilitation Medicine World Congress.

July 4, 2018
·
14 min read
Drug Development

Ipsen Announces CELESTIAL phase 3 Pivotal Trial Results in the New England Journal of Medicine

Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX® for previously treated advanced hepatocellular carcinoma (HCC)

July 4, 2018
·
13 min read
Deals

SQI Diagnostics to Extend Warrant Expiry of 5,330,000 Outstanding Common Share

SQI Diagnostics Inc. announced that it intends to extend the expiry of 5,330,000 outstanding common share purchase warrants of the Company

July 4, 2018
·
3 min read
Drug Development

Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine

Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX® (cabozantinib) for previously treated advanced hepatocellular carcinoma

July 4, 2018
·
15 min read
Media Advisory - Tomorrow will be busy in the Canopy world

Multiple press conferences and news releases will be issued by the Company, including Canopy Growth President and Co-CEO Mark Zekulin to hold media availability conference call on Company’s strategy for Latin America

July 4, 2018
·
1 min read